CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia

Overview

Journal Arterioscler Thromb Vasc Biol

Date 2017 Aug 26

PMID 28838920

Citations 12

Authors

Alexandra C Chadwick

Kiran Musunuru

Affiliations

Soon will be listed here.

Abstract

Although human genetics has resulted in the identification of novel lipid-related genes that can be targeted for the prevention of atherosclerotic vascular disease, medications targeting these genes or their protein products have short-term effects and require frequent administration during the course of the lifetime for maximal benefit. Genome-editing technologies, such as CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated 9) have the potential to permanently alter genes in the body and produce long-term and even lifelong protection against atherosclerosis. In this review, we discuss recent advances in genome-editing technologies and early proof-of-concept studies of somatic in vivo genome editing in mice that highlight the potential of genome editing to target disease-related genes in patients, which would establish a novel therapeutic paradigm for atherosclerosis.

Citing Articles

Vascular Extracellular Matrix in Atherosclerosis.

Di Nubila A, Dilella G, Simone R, Barbieri S Int J Mol Sci. 2024; 25(22).

PMID: 39596083 PMC: 11594217. DOI: 10.3390/ijms252212017.

Emerging Therapeutic Strategies in Cardiovascular Diseases.

Singh R, Chandi S, Sran S, Aulakh S, Nijjar G, Singh K Cureus. 2024; 16(7):e64388.

PMID: 39131016 PMC: 11317025. DOI: 10.7759/cureus.64388.

What did CRISPR-Cas9 accomplish in its first 10 years?.

Khlidj Y Biochem Med (Zagreb). 2023; 33(3):030601.

PMID: 37545694 PMC: 10373057. DOI: 10.11613/BM.2023.030601.

Gene editing for dyslipidemias: New tools to "cut" lipids.

Stankov S, Cuchel M Atherosclerosis. 2023; 368:14-24.

PMID: 36725417 PMC: 10493168. DOI: 10.1016/j.atherosclerosis.2023.01.010.

Prospective Advances in Genome Editing Investigation.

Isola G Adv Exp Med Biol. 2022; 1396:301-313.

PMID: 36454474 DOI: 10.1007/978-981-19-5642-3_19.

References

Lehrman M, Schneider W, Sudhof T, Brown M, Goldstein J, Russell D . Mutation in LDL receptor: Alu-Alu recombination deletes exons encoding transmembrane and cytoplasmic domains. Science. 1985; 227(4683):140-6. PMC: 4449727. DOI: 10.1126/science.3155573. View

Gregory S, Nazir S, Metcalf J . Implications of the innate immune response to adenovirus and adenoviral vectors. Future Virol. 2011; 6(3):357-374. PMC: 3129286. DOI: 10.2217/fvl.11.6. View

Ma Y, Zhang J, Yin W, Zhang Z, Song Y, Chang X . Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nat Methods. 2016; 13(12):1029-1035. DOI: 10.1038/nmeth.4027. View

Nishida K, Arazoe T, Yachie N, Banno S, Kakimoto M, Tabata M . Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science. 2016; 353(6305). DOI: 10.1126/science.aaf8729. View

Kim D, Lim K, Kim S, Yoon S, Kim K, Ryu S . Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. Nat Biotechnol. 2017; 35(5):475-480. DOI: 10.1038/nbt.3852. View

Wang M, Zuris J, Meng F, Rees H, Sun S, Deng P . Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci U S A. 2016; 113(11):2868-73. PMC: 4801296. DOI: 10.1073/pnas.1520244113. View

Maxwell K, Breslow J . Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004; 101(18):7100-5. PMC: 406472. DOI: 10.1073/pnas.0402133101. View

Tsai S, Zheng Z, Nguyen N, Liebers M, Topkar V, Thapar V . GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2014; 33(2):187-197. PMC: 4320685. DOI: 10.1038/nbt.3117. View

Ran F, Hsu P, Lin C, Gootenberg J, Konermann S, Trevino A . Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013; 154(6):1380-9. PMC: 3856256. DOI: 10.1016/j.cell.2013.08.021. View

10.

Ding Q, Regan S, Xia Y, Oostrom L, Cowan C, Musunuru K . Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell. 2013; 12(4):393-4. PMC: 3925309. DOI: 10.1016/j.stem.2013.03.006. View

11.

Ding Q, Strong A, Patel K, Ng S, Gosis B, Regan S . Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014; 115(5):488-92. PMC: 4134749. DOI: 10.1161/CIRCRESAHA.115.304351. View

12.

Hess G, Fresard L, Han K, Lee C, Li A, Cimprich K . Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat Methods. 2016; 13(12):1036-1042. PMC: 5557288. DOI: 10.1038/nmeth.4038. View

13.

Mali P, Aach J, Stranges P, Esvelt K, Moosburner M, Kosuri S . CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9):833-8. PMC: 3818127. DOI: 10.1038/nbt.2675. View

14.

Muruve D . The innate immune response to adenovirus vectors. Hum Gene Ther. 2005; 15(12):1157-66. DOI: 10.1089/hum.2004.15.1157. View

15.

Cho S, Kim S, Kim J, Kim J . Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 2013; 31(3):230-2. DOI: 10.1038/nbt.2507. View

16.

Abifadel M, Varret M, Rabes J, Allard D, Ouguerram K, Devillers M . Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2):154-6. DOI: 10.1038/ng1161. View

17.

Young S, Northey S, McCarthy B . Low plasma cholesterol levels caused by a short deletion in the apolipoprotein B gene. Science. 1988; 241(4865):591-3. DOI: 10.1126/science.3399894. View

18.

Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J . RNA-programmed genome editing in human cells. Elife. 2013; 2:e00471. PMC: 3557905. DOI: 10.7554/eLife.00471. View

19.

Miano J, Zhu Q, Lowenstein C . A CRISPR Path to Engineering New Genetic Mouse Models for Cardiovascular Research. Arterioscler Thromb Vasc Biol. 2016; 36(6):1058-75. PMC: 4882230. DOI: 10.1161/ATVBAHA.116.304790. View

20.

Guilinger J, Thompson D, Liu D . Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol. 2014; 32(6):577-582. PMC: 4263420. DOI: 10.1038/nbt.2909. View